| Systematic (IUPAC) name | |
|---|---|
| (17β)-17-ethynyl-17-hydroxyestr-4-en-3-one; (8R,9S,10R,13S,14S,17S)-17-ethynyl-17-hydroxy-13-methyl-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one |
|
| Clinical data | |
| AHFS/Drugs.com | International Drug Names |
| MedlinePlus | a604034 |
| Pregnancy cat. | ? |
| Legal status | ? |
| Pharmacokinetic data | |
| Bioavailability | 64% |
| Protein binding | >95% |
| Half-life | 7 hours |
| Identifiers | |
| CAS number | 68-22-4 |
| ATC code | G03AC01 G03DC02 |
| PubChem | CID 6230 |
| DrugBank | APRD00679 |
| ChemSpider | 5994 |
| UNII | T18F433X4S |
| KEGG | D00182 |
| ChEBI | CHEBI:7627 |
| ChEMBL | CHEMBL1162 |
| Chemical data | |
| Formula | C20H26O2 |
| Mol. mass | 298.419 g/mol |
| SMILES | eMolecules & PubChem |
|
|
| (what is this?) (verify) |
|
Norethisterone (or norethindrone) (or 19-nor-17α-ethynyltestosterone) is a molecule used in some combined oral contraceptive pills, progestogen only pills and is also available as a stand-alone drug. It is a progestogen and can be used to treat premenstrual syndrome, painful periods, abnormal heavy bleeding, irregular periods, menopausal syndrome (in combination with oestrogen), or to postpone a period. It is also commonly used to help prevent uterine hemorrhage in complicated non-surgical or pre-surgical gynecologic cases. Norethindrone was the first orally highly active progestin to be synthesized. It was synthesized for the first time by chemists Luis Miramontes, Carl Djerassi, and George Rosenkranz at Syntex in Mexico City in 1951.[1] It was the progestin used in one of the first two oral contraceptives. It is often used as the related ester, norethisterone acetate.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||